Clinical Trial Update: Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating trilaciclib in combination with eribulin for locally advanced or metastatic triple-negative brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Cosela (trilaciclib)
• Halaven (eribulin)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING